新型64Cu标记稀土切伦科夫光动力凝胶微球用于肝癌栓塞联合治疗研究
批准号:
32101155
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
陈川
依托单位:
学科分类:
纳米生物学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
陈川
中文摘要
肝癌是临床常见恶性肿瘤,介入栓塞化疗已广泛用于肝癌临床治疗但常遇耐药瓶颈。以核素切伦科夫辐射(CR)为光源的自激发光动力疗法(PDT)有望联合介入栓塞突破传统疗法瓶颈,但CR较低的发光强度已成为限制该疗法发展的关键。基于课题组前期在核壳稀土纳米晶发光增强、稀土发光能量传递机制和PDT抗肿瘤治疗方面的研究基础,本项目拟通过对高原子序数Lu掺杂核壳稀土纳米晶进一步标记核素64Cu,提出一种基于双辐射(CR和β辐射)增强型PDT凝胶微球的肝癌介入栓塞治疗新策略:1)研究核素CR和β辐射对Lu掺杂核壳稀土纳米晶的发光增强机制;2)以pH响应型聚合物水凝胶为载体制备具有自激发PDT抗肿瘤活性的凝胶栓塞微球,阐明微球辐射增强活性氧产生和细胞损伤机制;3)开展自激发PDT凝胶微球用于兔VX2肝癌的介入栓塞疗效机制研究。本项目有望为放射性核素自激发PDT用于肝癌等深部肿瘤的治疗研究提供科学依据和理论支持。
英文摘要
Hepatocellular carcinoma (HCC) is a common clinical malignancy. Transcatheter arterial chemoembolization (TACE) has been widely used in the clinical treatment of HCC, but drug resistance remains the main challenge. Photodynamic therapy (PDT) with Cherenkov radiation (CR) as the endogenous light source is expected to break through the bottleneck of traditional treatment in combination with interventional embolization. Still, the low photon production yield of CR has become a key factor restricting the development of this new type of PDT. Therefore, strategies to amplify the therapeutic effect of CR-induced PDT are urgently needed. Based on the preliminary researches of luminescence enhancement in lanthanide‐doped core–shell upconversion nanocrystals, energy transfer mechanism of lanthanide‐doped core–shell nanoarchitectures and PDT induced-HepG2 cell apoptosis, we designed a new type of pH-responsive hydrogel embolization microsphere based on 64Cu-labeled high-Z Lu-doped core-shell nanoarchitecture for efficient interventional embolization of HCC. Through the mechanism analysis of the interaction and energy transfer between CR, β radiation of radionuclides, and high-Z Lu-doped core-shell nanocrystal, we will provide the theoretical support for designing self-stimulated PDT hydrogel embolization microspheres with high ROS generation ability and biocompatibility for deep cancer treatment. Meanwhile, the anti-tumor effect of self-stimulated PDT hydrogel embolization microspheres will be investigated at the cell level and in the subcutaneous tumor model of mice. Finally, the therapeutic evaluation and mechanism study of 64Cu-labeled self-stimulated PDT hydrogel embolization microspheres in interventional embolization of rabbit VX2 liver cancer will be carried out under PET-CT guidance. The implementation of this project is expected to provide new ideas and scientific basis for radionuclide self-stimulated PDT in the treatment of HCC or other deep tumors.
肝癌是临床常见恶性肿瘤,是世界上许多地区导致人类死亡的主要原因,更是对医疗保健提出了重大挑战。目前,肝癌介入栓塞联合放疗与化疗是不能手术肝癌患者的主要治疗方式。然而,这些疗法会导致耐药和潜在的毒副作用,影响患者的预后。光动力疗法(PDT)是一种临床认可的癌症治疗方法,它依赖于外部光激活光敏剂所产生的细胞毒性物质来杀伤肿瘤细胞,但该疗法目前依然受限于光源的穿透深度而无法广泛应用。以核素切伦科夫辐射(CR)为光源的自激发光动力疗法(CR-PDT)有望联合介入栓塞突破传统疗法瓶颈,但CR较低的发光强度已成为限制该疗法发展的关键。基于此,本项目课题组利用稀土掺杂上转换核壳纳米粒子(UCNPs)和64Cu核素结合,制备得到了新型64Cu标记自激发PDT光敏剂,并且进一步在光敏剂表面通过超薄SiO2修饰和近红外花菁敏化荧光染料IR-806的修饰,从而实现了40倍以上的敏化荧光增强,显著提高了能量给体和能量受体之间的荧光共振能量转移(FRET)效率,最终通过聚合物包裹修饰得到尺寸大小合适的64Cu标记自激发PDT介入栓塞微球,阐明了该微球64Cu核素辐射增强活性氧产生和细胞损伤机制,开展了自激发PDT凝胶微球用于兔VX2肝癌的介入栓塞疗效研究,最终取得了较好的自激发PDT肝癌治疗效果。在项目开展过程中,我们不仅重视项目最终的实验结果,还对研究过程中包括核壳稀土纳米晶UCNPs荧光增强机制、近红外染料敏化增强稀土发光机理、稀土发光能量传递机制等各因素进行了细致的调控和深入研究。本项目有望为放射性核素自激发PDT用于肝癌等深部肿瘤的治疗研究提供科学依据和理论支持。
国内基金
海外基金